BERLIN, April 24, 2008 (PRIME NEWSWIRE) -- Jerini AG (FSE:JI4) has received a not approvable letter from the FDA for its New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE). The not approvable letter outlines areas of concern that the company is now going to review with the agency.
Jerini is expecting an opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) for Icatibant in the treatment of HAE later today.
ISIN: DE0006787476
Regulated Market / Prime Standard; Frankfurt Stock Exchange, Germany
Ad hoc English: http://hugin.info/135931/R/1213142/252144.pdf